Highlights

  • Second quarter net loss was USD 9,006 thousand against Net Income of USD 5,151 thousand.
  • Operating expenses were USD 9,468 thousand against USD 2,928 thousand.
  • Cash and cash equivalents were USD 2,366 thousand at June 30, 2026.
  • The company changed its name from Plus Therapeutics effective August 3, 2026.

Cerenome, Inc. (NASDAQ:CNSY) shares were trading near their all-time low at USD 0.6784 on November 6, 2026, up 1.27% on the day. The company, previously known as Plus Therapeutics, reported a second quarter net loss of USD 9,006 thousand, or USD 1.31 per share.

Cerenome is a U.S. healthcare company focused on central nervous system cancers through three Business areas: precision diagnostics, targeted radiopharmaceutical therapeutics and proprietary data analytics. Effective August 3, 2026, it filed an amendment to change its name from Plus Therapeutics.

Results for the Quarter and Six Months

Total operating expenses were USD 9,468 thousand against USD 2,928 thousand, and the operating loss was USD 9,057 thousand against USD 1,538 thousand. The company reported a net loss of USD 9,006 thousand against net income of USD 5,151 thousand in the second quarter of 2025.

The loss per share was USD 1.31 against basic Earnings of USD 0.62 and a diluted loss of USD 0.16. For the six months, total operating expenses were USD 17,615 thousand against USD 7,523 thousand, and the net loss was USD 15,952 thousand against USD 12,250 thousand, or USD 2.36 per share against USD 12.54.

Grant Revenue

The company recognized grant Revenue of USD 0.4 million for the quarter and USD 1.4 million for the six months from the CPRIT contract, against USD 1.4 million and USD 2.4 million a year earlier. The filing says the grant covers CPRIT's share of costs for development of rhenium-186 obisbemeda.

Cash and Balance Sheet

Cash and cash equivalents were USD 2,366 thousand at June 30, 2026 against USD 4,256 thousand at December 31, 2025. Net cash used in Operating Activities was USD 13,370 thousand for the six months against USD 11,970 thousand. Net cash provided by financing activities was USD 10.1 million.

Total Assets were USD 14,030 thousand against USD 16,325 thousand. Total liabilities were USD 8,567 thousand against USD 12,329 thousand, and total stockholders' Equity was USD 5,463 thousand against USD 3,996 thousand. The accumulated Deficit was USD 531,817 thousand.

Funding Needs and Listing

The filing states that the company has an ongoing need to raise additional cash from outside sources to fund clinical development programs, launch the CNSide Test and fund other operations, with no assurance it will be able to continue doing so.

On April 20, 2026, Nasdaq notified the company that it had regained compliance with the minimum bid requirement after implementation of a reverse stock split. The company had 7,589,625 shares outstanding as of August 5, 2026.